In summary, the JAK2 and TGF-β1 signaling pathways were found to be involved in the development of SSc-ILD, and its inhibitor baricitinib is a potential therapeutic candidate for the treatment of murine and human SSc. This evidence concerns the gene TGFB1 and systemic sclerosis.